MarketWatch.com - Top Stories

Why this newly public biotech could become a force in obesity treatments

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.

Feb 25, 2025 - 19:46
 0
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up.
Read More

Tags:

Previous Article

MSC Cruises reports man overboard; Celebrity Cruises loses a legend

Next Article

Tuesday links: increased concentration

Related Posts

Travelers expects $1.7 billion insured loss from the California wildfires. Analysts still expect a profit.

Travelers expects $1.7 billion insured loss from the Ca...

Feb 11, 2025  0

Oil prices post back-to-back losses on prospect of Russia-Ukraine peace talks

Oil prices post back-to-back losses on prospect of Russ...

Feb 13, 2025  0

AMC’s stock climbs as improving box office brings better-than-expected fourth-quarter revenue

AMC’s stock climbs as improving box office brings bette...

Feb 25, 2025  0